SinoMab hits Hong Kong with $223m IPO
SinoMab BioScience, a biopharmaceutical firm, has started taking orders for its up to HK$1.7bn ($223m) Hong Kong IPO.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: